October 2021 in “Revista Medicina Cutánea Ibero-Latino-Americana” This case report describes a patient who developed PRIDE syndrome-associated skin issues, including a pruritic papulopustular rash and alopecia, after starting treatment with the EGFR inhibitor erlotinib.
August 2024 in “Postgraduate Medical Journal” A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.
8 citations
,
August 1997 in “Australasian Journal of Dermatology” This review discusses the distinctive non-infective skin presentations of HIV infection from a dermatological perspective and reports no new clinical findings.
June 2026 in “Indian Journal of Postgraduate Dermatology” In this reported case, a 50-year-old man developed an acneiform rash, a common skin side effect of EGFR inhibitor therapy, after starting lapatinib for breast cancer; treatment with doxycycline and hydrocortisone cream led to significant improvement within one week.
29 citations
,
September 2017 in “Oncology and therapy” This review discusses the common dermatologic side effects of epidermal growth factor receptor inhibitors and provides practical guidance for recognizing and managing these effects; it reports no new clinical results.